Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of Actimab-A in combination of CLAG-M in patients with acute myeloid leukemia

Next Previous
X
Search
Trial Profile

A phase 2 study of Actimab-A in combination of CLAG-M in patients with acute myeloid leukemia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Lintuzumab Ac-225 (Primary) ; Mitoxantrone (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 03 Apr 2023 According to an Actinium Pharmaceuticals media release, company expects to initiate under the NCI CRADA the late-stage development including this trial in combinations as a backbone therapy for r/r AML in the 2H 2023
    • 16 Dec 2019 New trial record
    • 09 Dec 2019 According to a Actinium Pharmaceuticals media release, the company is planning to advance this combination of Actimab-A with CLAG-M in this phase 2 study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top